Hindustan Laboratories Limited

Hindustan Laboratories Limited (New IPO): GMP, Profit, Price & expert review

by

Hindustan Laboratories Limited is an Indian pharmaceutical company primarily engaged in the large-scale manufacturing and supply of generic medicines, especially under business-to-government (B2G) contracts for central and state government healthcare agencies. It focuses on providing cost-effective off-patent generic formulations across a wide range of therapeutic segments.

It supplies its products to government institutions across 27 Indian states and union territories, indicating wide national distribution.

Hindustan Laboratories Limited was incorporated in the year 2017 & currently Mr. Rajesh V. Doshi serves as the Managing Director of the company.

Hindustan Laboratories Limited has filed DRHP with SEBI for a proposed IPO with an issue size of 14,100,000 Equity Shares consisting Fresh Issue of 5,000,000 Equity Shares & Offer for Sale (OFS) of 9,100,000 Equity Shares.

Subscription date to apply for the IPO is yet to be announced. Price band for the IPO is also pending to be declared.

Check DRHP
Check IPO Allotment
Visit Official Website
Issue Size:14,100,000 Equity Shares
Fresh Issue:5,000,000 Equity Shares
Offer for Sale:9,100,000 Equity Shares
Price Range:TBA
Lot Size:TBA
GMPPending

Hindustan Laboratories Limited important data points

Revenue, PAT, EBITDA

YearFiscal 2025
Networth₹ 178.73 Cr
Revenue:₹ 219.74 Cr
EBITDA₹ 53.87 Cr
PAT₹ 41.26 Cr
EBITDA Margin:~24.52%
PAT Margin~ 18.78%
Face Value:₹ 10 Per Equity Shares

IPO important dates

Open Date:TBA
Close Date:TBA
Anchor Investor BiddingTBA
Allotment Date:TBA
Refunds & Demat CreditTBA
Tentative Listing Date:TBA

Use of Proceeds

PurposeAmount
Marketing & Promotions~ ₹ 00 Cr
Technology & Infrastructure~ ₹ 00 Cr
Working capital requirement~ ₹ 72.5 Cr
General Corporate PurposeBalance

Hindustan Laboratories Limited Financial Data

202320242025
Revenue (₹ Cr)₹ 172.3₹ 186.4₹ 219.7
PAT (₹ Cr)₹ 22.3₹ 34.1₹ 41.3
Asset (₹ Cr)₹ 145.4₹ 176.3₹ 225.5
Net Worth (₹ Cr)₹ 103.2₹ 137.3₹ 178.7

Hindustan Laboratories Ltd IPO Grey Market Premium

DateIPO PriceIPO GMPProfit per lot
03-Mar₹ –₹ –₹ –
02-Mar₹ –₹ –₹ –
01-Mar₹ –₹ –₹ –
28-Feb₹ –₹ –₹ –
27-Feb₹ –₹ –₹ –
Hindustan Laboratories Limited

Hindustan Laboratories Limited IPO Pros & Cons

Strengths:

  • Strong B2G (business-to-government) focus ensures steady demand and bulk orders.
  • Operates in the defensive pharma sector, which is resilient during economic downturns.
  • Wide pan-India presence across 27+ states/UTs through government tenders.
  • Focus on low-cost generic medicines, aligned with India’s public healthcare push.
  • IPO filing improves brand visibility and funding access for future expansion.

Risks:

  • Heavy dependence on government tenders, which can impact margins and cash flows.
  • No disclosed retail market presence, limiting brand recall among consumers.
  • Price band and valuation clarity pending, increasing uncertainty for investors.
  • Pharma business exposed to regulatory, pricing, and compliance risks.
  • Limited public data on market share and long-term profitability metrics.

Hindustan Laboratories Limited Promoters – Pre offer equity (Approx)

Promoters%Shares
Rajesh Vasantray Doshi~99.99%

Hindustan Laboratories Limited Lot Size details

Application TypeLot SizeNo. of LotsNo. of SharesInvestment Amount
Retail(Min)–1–₹ –
Retail (Max)–13–₹ –
Small HNI (Min)–14–₹ –
Small HNI (Max)–66–₹ –
Big HNI (Min)–67–₹ –

Lead Managers / Registrars of Hindustan Laboratories Limited 

Lead / Book Running Lead ManagersChoice Capital Advisors Private Limited
Registrar (RTA)MUFG Intime India Private Limited

Hindustan Laboratories Limited FAQ

  • It is a pharmaceutical manufacturer focused on large-scale generic medicines supplied mainly to government institutions under a business-to-government (B2G) model.
  • Hindustan Laboratories is raising funds via IPO to fund working capital needs and support general corporate purposes to expand operations.
  • The issue size of the IPO is ~1.41 Cr equity shares. It will be listed on the BSE & NSE platform.
  • Risk factors include dependence on government tenders, pricing pressures, regulatory changes, and competition in generic pharma.
  • Upsides include consistent demand for affordable medicines, extensive national reach, and growth potential in public healthcare supply contracts.
  • You can apply for the IPO via ASBA through bank net banking, UPI on trading apps, or through your broker when the IPO opens for subscription.

For more amazing blogs click here (IPO Corner).

Leave a comment